SunitaDwivedy(Dwivedy)NastaMDFACP

PubMed

• 314 citations
  Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
  Anthony R. Mato, Chadhi Nabhan, Meghan C. Thompson, Nicole Lamanna, Danielle M. Brander
  Haematologica. 2018-05-01
• 94 citations
  Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy.
  Elise A. Chong, Cécile Alanio, Jakub Svoboda, Sunita D. Nasta, Daniel J. Landsburg
  Blood. 2021-09-09
• Mutation analysis performed on tumor biopsies from patients with newly-diagnosed germinal center aggressive B cell lymphomas.
  Daniel J Landsburg, Jennifer J D Morrissette, Stephen J Schuster, Sunita D Nasta, James N Gerson
  Oncotarget. 2022-11-17

Journal Articles

• Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-Exposure SARS-CoV-2 Prophylaxis Among Health Care Workers  
  Matthew C Hyman, Ian Frank, Scott E Hensley, Saar Gill, Dan T Vogl, Ivan Maillard, Daria V Babushok, Alexander C Huang, Sunita D Nasta, Jennifer C Walsh, Michael C Mil..., JAMA Internal Medicine
• International, Evidence-Based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman Disease  
  Aaron Goodman, Corey Casper, Sudipto Mukherjee, Peter Voorhees, Angela Dispenzieri, David C Fajgenbaum, Amy Chadburn, Razelle Kurzrock, Raj Jayanthan, Sunita Nasta, Th..., Blood
• Non-Viral RNA Chimeric Antigen Receptor Modified T Cells in Patients with Hodgkin Lymphoma  
  Stephan A Grupp, Sunita Dwivedy Nasta, Susan R Rheingold, Daniel J Landsburg, Carl H June, Jakub Svoboda, Stephen J Schuster, Saar I Gill, David L Porter, Bruce L Levine, Blood

Abstracts/Posters

• Concurrent Use of Novel Agents and Radiation Is Tolerated in Lymphoma Patients
  Sunita Dwivedy Nasta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors
  Sunita D Nasta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes for Double Hit Lymphoma Patients Identified Via Routine Vs Selective Testing for MYC Rearrangement
  Sunita Dwivedy Nasta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas
  Sunita Dwivedy Nasta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas
  Sunita D Nasta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications
  Sunita Dwivedy Nasta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes of Patients with Refractory Peripheral T-Cell Lymphoma, Angioimmunoblastic and Other Nodal Lymphomas of T Follicular Helper-Cell Origin (OPerA)
  Sunita Dwivedy Nasta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Mu...
  Sunita Dwivedy Nasta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) Following Solid Organ (SOT) or Allogeneic Hematop...
  Sunita Dwivedy Nasta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution Experience 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical Outcomes of Venetoclax Therapy in Patients with Relapsed/Refractory (r/r) Non Hodgkin Lymphomas (NHL) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all